FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata

Related Clinical Trials

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

Highlighted Terms

NCT04797650deuruxolitinibLeqselviNCT04518995National Alopecia Areata FoundationU.S. Food and Drug AdministrationSun Pharmaceutical Industries LimitedAlopecia Areata

Related News

drugs.com

FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata

FDA approves Leqselvi (deuruxolitinib), an oral JAK inhibitor for severe alopecia areata treatment.